Ip Group/£IPO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Ip Group
- Ticker
- £IPO
- Sector
- Finance
- Primary listing
- LSE
- Employees
- 64
- Headquarters
- London, United Kingdom
- Website
- www.ipgroupplc.com
Ip Group Metrics
BasicAdvanced
£645M
4.75
£0.15
1.31
-
Price and volume
Market cap
£645M
Beta
1.31
52-week high
£0.77
52-week low
£0.48
Average daily volume
1.7M
Financial strength
Current ratio
36.571
Quick ratio
36.571
Long term debt to equity
0.119
Total debt to equity
0.119
Interest coverage (TTM)
3.47%
Profitability
EBITDA (TTM)
22.65
Gross margin (TTM)
100.00%
Net profit margin (TTM)
362.47%
Operating margin (TTM)
57.07%
Effective tax rate (TTM)
-1.44%
Revenue per employee (TTM)
£610,000
Management effectiveness
Return on assets (TTM)
1.26%
Return on equity (TTM)
14.94%
Valuation
Price to earnings (TTM)
4.75
Price to revenue (TTM)
16.703
Price to book
0.64
Price to tangible book (TTM)
0.64
Price to free cash flow (TTM)
-82.244
Free cash flow yield (TTM)
-1.22%
Free cash flow per share (TTM)
-0.009
Growth
Revenue change (TTM)
-129.88%
Earnings per share change (TTM)
-206.71%
3-year revenue growth (CAGR)
-11.06%
10-year revenue growth (CAGR)
23.53%
3-year earnings per share growth (CAGR)
21.92%
10-year earnings per share growth (CAGR)
12.69%
What the Analysts think about Ip Group
Analyst ratings (Buy, Hold, Sell) for Ip Group stock.
Analyst projections of the future price of Ip Group stock.
Bulls say / Bears say
NAV per share rose 3.2% to 113.9p in H1 2026, taking total NAV above £1bn; the £31.2m profit and £239m of gross cash provide a stronger base for investment and shareholder returns. (Investegate)
IP Group generated £68.7m from exits in H1 and sold 10 million Oxford Nanopore shares for about £21m in October, while retaining a 7.23% stake. The sale boosts liquidity without removing its exposure to further growth. (Investegate, Investegate)
Portfolio companies raised £543m in H1, up from £372m a year earlier, while IP Group supplied only around 5% of the total. This outside funding helps portfolio businesses progress without requiring the Group to provide all the capital. (Investegate)
Portfolio valuations remain vulnerable: Diffblue and Aqdot were written down by £5.2m and £3.4m respectively, while 43% of funding rounds in the half were down rounds. Further weak fundraising or operating performance could reduce NAV. (Stockopedia)
The £152m Pfizer obesity royalty asset depends on drug programmes that still face clinical, regulatory and commercial risks; setbacks could reverse some of the £27m H1 valuation uplift. (Investegate, Proactive Investors)
After the H1 update, the shares traded at about a 41% discount to an analyst’s fair value, showing that NAV growth and exits have not yet won full market confidence. If that discount persists, improving portfolio values may not translate into shareholder returns. (Equity Development)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2026.
Ip Group Financial Performance
Revenues and expenses
Ip Group Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Ip Group
AllUSDGBPEUR
Fund name | Fund size | £IPO weighting |
|---|---|---|
iShares Listed Private Equity$IDPE | $843M | 0.34% |
iShares Listed Private Equity£IPRV | $843M | 0.34% |
Vanguard FTSE 250£VMIG | £569M | 0.21% |
Vanguard FTSE 250£VMID | £1.5B | 0.21% |
iShares FTSE 250£MIDD | £672M | 0.20% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.